Drug Profile
Zedenoleucel - Marker Cell Therapy
Alternative Names: Autologous cytotoxic T-cell therapeutic - Marker Cell Therapeutics; MT-401; MT-401-OTS; MultiTAA T cells Stage; MultiTAA T-cell therapy; MultiTAA-specific T cells; TAA-specific CTLs; ZelenoleucelLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Marker Therapeutics
- Developer Baylor College of Medicine; Marker Cell Therapy
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Acute myeloid leukaemia; Breast cancer
- Phase I/II Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma; Sarcoma
- No development reported Myelodysplastic syndromes
- Discontinued Lymphoma; Ovarian cancer
Most Recent Events
- 25 Mar 2024 The US FDA grants an IND to investigate MT-401 as an “Off-the-Shelf” (MT-401-OTS) product in patients with Acute myeloid leukemia or Myelodysplastic Syndrome before March 2024
- 08 Jan 2024 Efficacy and adverse events data from a phase II ARTEMIS trial in Acute myeloid leukaemia released by Marker Therapeutics
- 31 Dec 2023 Marker Therapeutics terminates the phase II ARTEMIS trial for Acute myeloid leukaemia (Adjuvant therapy, Second-line therapy or greater) in the US (IV, Infusion), because the company intends to prioritize the MT-401-OTS program, prior to December 2023 (NCT04511130)